bioMérieux

Earnings Release • Oct 26, 2023

bioMérieux – Third-Quarter 2023 Business Review

• +8.0% sales organic growth over the first nine months of the year:
  • €2,668 million in sales
  • +4.2% as reported
• Q3 sales organic growth at +7.1% (+10.3% excluding BIOFIRE® respiratory panels), on par with expectations
• BIOFIRE® non-respiratory panels grew by +24% in Q3 thanks to successful crossselling by leveraging the large BIOFIRE® installed base and the broadest menu in the market
• Remarkable resilience of the BIOFIRE® respiratory panels sales (-2% over the 9 months period, -5% in Q3) in a 2023 post COVID environment, demonstrating the value of the syndromic solution
• Strong momentum in clinical microbiology (+11% in Q3) thanks to the continued uptake of the VITEK® MS PRIME and the relevance of the product portfolio to support the fight against Antimicrobial Resistance
• Promising launch of BIOFIRE® SPOTFIRE® with close to 400 installed instruments at the end of September 2023 and high customers interest. On-going geographical expansion out of the US with the start in Japan, and broadening of the menu through the FDA filing of the BIOFIRE® SPOTFIRE® Respiratory Sore Throat panel in October
• Confirmation of the 2023 guidance:
  • Organic sales growth between +4 and +6%
  • Contributive operating income before non-recurring items should be in a range of €600 million to €630 million

Pierre Boulud, Chief Executive Officer, said: "bioMérieux delivered a solid performance during the third quarter of 2023. The BIOFIRE® non-respiratory panels kept on growing at a very strong pace while respiratory panels sales were resilient. In addition, the microbiology franchise performed very well, driven by both volumes and prices increases. We expect BIOFIRE® respiratory panels sales to be lower in Q4 2023 than in Q4 2022, inflated by the triple-demic, but we are confident to achieve our full year targets."

Marcy l'Étoile, France, October 26, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023.

SALES

NB: Unless otherwise stated, sales growth is expressed at constant exchange rates and scope of consolidation (like-for-like).

Consolidated sales amounted to €2,668 million for the first nine months of 2023 versus €2,560 million for the prior-year period, representing a growth of +4.2% as reported. Organic growth (at constant exchange rates and scope of consolidation) reached +8.0% for the first nine months of the year. Changes in exchange rates

had a negative €92 million impact over 9 months, due to the appreciation of the euro against most of the other currencies and mainly the US dollar, the Chinese yuan and the Argentinian peso.

Analysis of sales

In € millions
SALES - NINE MONTHS ENDED SEPTEMBER 30, 2022	2,560
Currency effect	-92	-3.6%
Changes in scope of consolidation	0
Organic growth (at constant exchange rates and scope of consolidation)	+204	+8.0%
SALES - NINE MONTHS ENDED SEPTEMBER 30, 2023	2,668	+4.2%

NB: A definition of the currency effect and of changes in the scope of consolidation is provided at the end of this press release.

ANALYSIS OF SALES BY APPLICATION

Sales by Application In € millions	Q3 2023	Q3 2022	% change as reported	% change at constant exchange rates and scope of consolidation	9 months ended Sept. 30, 2023	9 months ended Sept. 30, 2022	% change as reported	% change at constant exchange rates and scope of consolidation
Clinical Applications	760.9	763.0	-0.3%	+7.2%	2,244.8	2,154.7	+4.2%	+7.9%
Molecular biology	327.9	333.5	-1.7%	+5.5%	993.1	956.8	+3.8%	+6.3%
Microbiology	321.6	311.8	+3.2%	+10.8%	930.9	853.9	+9.0%	+13.4%
Immunoassays	94.2	101.4	-7.0%	+0.5%	281.4	299.8	-6.1%	-1.4%
Other lines(1)	17.1	16.4	+4.4%	+18.9%	39.4	44.2	-10.8%	-0.4%
Industrial Applications(2)	137.5	139.0	-1.0%	+6.3%	423.7	405.2	+4.6%	+8.3%
TOTAL SALES	898.4	902.0	-0.4%	+7.1%	2,668.5	2,559.9	+4.2%	+8.0%

(1) Including BioFire Defense, R&D-related revenue arising on clinical applications

(2) Including R&D-related revenue arising on industrial applications.

• Clinical Applications sales (84% of total sales), increased by 7% year-on-year over the quarter compared to 2022:
  • In molecular biology, the non-respiratory BIOFIRE® panels sales grew at a very dynamic pace, up 24% versus prior year. Respiratory panels sales, as expected, decreased by 5% versus 2022 Q3 which was exceptionally high because of the COVID pandemic. The BIOFIRE® installed base has continued to expand to 24,800 units at September 30, 2023, versus 24,300 at June 30, 2023. The BIOFIRE® SPOTFIRE® installed base reached 375 instruments at the end of September 2023, illustrating the strong market interest for this solution.
  • In microbiology, the strong momentum has continued, with a double-digit growth in both reagents and instruments sales supported by prices and volumes increases. Reagents sales growth has been led by both the VITEK® automated ID/AST and blood culture BACT/ALERT® ranges. Instruments sales were mainly driven by the continued uptake of VITEK®MS Prime.
  • In immunoassays, sales recorded a slight positive performance, lifted by an overall growth in VIDAS reagents, the continued decrease of the sales of the procalcitonin determination tests (PCT) being compensated by a double-digit growth of other parameters sales.
• Industrial Applications sales (16% of total sales), moved up by more than 6%, reaching nearly €138 million for third-quarter 2023. The sales growth has been fueled by a 9% growth in reagents sales thanks to both prices and volumes increases, partly offset by lower equipment demand.

ANALYSIS OF SALES BY REGION

Sales by Region In € millions	Q3 2023	Q3 2022	% change as reported	% change at constant exchange rates and scope of consolidation	9 months ended Sept. 30, 2023	9 months ended Sept. 30, 2022	% change as reported	% change at constant exchange rates and scope of consolidation
Americas	439.8	454.6	-3.3%	+5.7%	1,323.7	1,287.0	+2.9%	+6.0%
North America	379.6	398.4	-4.7%	+2.9%	1,151.5	1,130.8	+1.8%	+3.8%
Latin America	60.2	56.2	+7.1%	+26.4%	172.2	156.2	+10.3%	+21.8%
EMEA (1)	293.1	274.4	+6.8%	+9.7%	863.8	811.0	+6.5%	+9.1%
Asia Pacific	165.5	173.0	-4.4%	+6.5%	481.0	461.9	+4.1%	+11.6%
TOTAL SALES	898.4	902.0	-0.4%	+7.1%	2,668.5	2,559.9	+4.2%	+8.0%

(1) Europe, the Middle East and Africa

• Sales in the Americas (50% of the consolidated total) reached €440 million in third-quarter 2023, an increase of nearly 6% on third-quarter 2022.
  • In North America (43% of the consolidated total), activity has been buoyed by a strong performance of the BIOFIRE® non-respiratory panels, the microbiology applications, especially VITEK® automated ID/AST, as well as the promising start of SPOTFIRE®, partially compensated by the lower sales in BIOFIRE® respiratory panels (versus a high basis of comparison in Q3 2022) and procalcitonin determination assays (PCT).
  • Latin America recorded robust organic growth, thanks to a double-digit growth in reagents sales in all the clinical applications franchises as well as in industrial applications.
• Sales in the Europe – Middle East – Africa region (32% of the consolidated total) came to €293 million for the 2023 third-quarter, up nearly 10% year-on-year driven by a double-digit growth in microbiology key ranges, BIOFIRE® panels (both respiratory and non-respiratory) and Industrial Applications.
• Sales in the Asia Pacific region (18% of the consolidated total) amounted to €165 million for the third quarter of 2023, up more than 6% from the prior-year period. In Clinical Applications, remarkable performance of all the countries with the exception of Japan impacted by the stepdown, compare to previous year, of the COVID-related demand for the BIOFIRE® respiratory panels. In Industrial Applications, the performance has been very dynamic across the region, with the exception of China.

EVENTS OF THIRD-QUARTER 2023 AND SUBSEQUENT EVENTS

bioMérieux submits Dual 510(k) & CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

The BIOFIRE® SPOTFIRE® R/ST Panel is a unique multiplex PCR test capable of detecting 15 of the most common bacteria, viruses, and viral subtypes responsible for respiratory or sore throat infections in about 15 minutes. Samples can be taken using either a nasopharyngeal or throat swab, depending on whether a respiratory tract infection or pharyngitis is suspected. The BIOFIRE® SPOTFIRE® solution allows bioMérieux to further expand its syndromic testing technology outside of the traditional clinical laboratories to Point-of-Care testing locations, offering healthcare professionals the ability to deliver results to patients during their visit. The BIOFIRE® SPOTFIRE® R/ST Panel is already CE-marked (IVDD) to address the European market.

bioMérieux announces CE-marking of VIDAS® TBI (GFAP, UCH-L1), a test for improved assessment of patients with mild traumatic brain injury, including concussion

This accurate and objective tool can help reduce the number of unnecessary head Computed Tomography (CT) scans performed for mild Traumatic Brain Injury (mTBI) patients and to decrease Emergency Department overcrowding by predicting the absence of acute intracranial lesions (ICL) following a head trauma. VIDAS® TBI (GFAP, UCH-L1) fills a gap in patient screening methods by safely ruling out ICLs and offering objective information to help determine if a CT-scan is necessary in adults, together with clinical information. VIDAS® TBI (GFAP, UCH-L1) measures the concentration of GFAP and UCH-L1, two brain biomarkers that are released into the bloodstream starting from the first hour following a brain injury.

bioMérieux makes strategic investment in Oxford Nanopore

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics ("IVD") announced on October 19th, 2023 that bioMérieux made an immediate £70M investment in Oxford Nanopore through the subscription of ordinary shares (which equates to 3.5% of Oxford Nanopore's voting rights as at 13 October 2023). In addition, on October 19th, 2023, bioMérieux completed the acquisition of a further 3.4% of Oxford Nanopore's shares on the secondary market.

Through this investment and the partnership announced in April 2023, the two companies intend to leverage Oxford Nanopore's ground-breaking nanopore-based IVD solution and bioMérieux's IVD expertise in R&D, Regulatory, Medical and Market Access. As part of the transaction, the two companies will establish an IVD Advisory Board to advance nanopore technology into routine clinical use.

INVESTOR PRESENTATION

bioMérieux will hold an investor presentation on Wednesday, October 26, 2023 at 3:00 pm Paris time (GMT+1). The presentation will be given in English and will be accessible via webcast under following link:

https://event.webcasts.com/starthere.jsp?ei=1636345&tp\_key=ec82aa00f6

If you are unable to join the webcast URL, please join audio conference with:.

France	Europe	United States
+33 (0)1 70 72 25 50	+44 (0)330 165 3655	+1 323-994-2093
	Access code: 874 0219

INVESTOR CALENDAR

Fourth-quarter 2023 sales and 2023 financial results March, 14th 2024

Notes and definitions

The above forward-looking statements are based, entirely or partially, on assessments or judgments that may change or be modified, due to uncertainties and risks related to the Company's economic, financial, regulatory and competitive environment, notably those described in the 2022 Registration Document. Accordingly, the Company cannot give any assurance nor make any representation as to whether the objectives will be met. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange.

Currency effect: this is established by converting actual numbers at the average rates of year y-1. In practice, those rates are either average rates communicated by the ECB, or hedged rates if hedging instruments have been set up. Argentina and Turkey are considered in bioMérieux's accounts since 2022 in a state of hyperinflation.

Changes in scope of consolidation: these are determined:

• for acquisitions in the period, by deducting from sales for the period the amount of sales generated during the period by acquired entities as from the date they entered the consolidated reporting scope;
• for acquisitions in the previous period, by deducting from sales for the period the amount of sales generated in the months in the previous period during which the acquired entities were not consolidated;
• for disposals in the period, by adding to sales for the period the amount of sales generated by entities sold during the previous period in the months of the current period during which these entities were no longer consolidated;
• for disposals in the previous period, by adding to sales for the period the amount of sales generated during the previous period by the entities sold.

BIOMÉRIEUX GAME CHANGER FOR 60 YEARS

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached €3.6 billion, with over 93% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website: www.biomerieux.com

CONTACTS

Investor Relations

bioMérieux Aymeric Fichet Tel.: +33 (0)4 78 87 20 00 investor.relations@biomerieux.com

Media Relations

bioMérieux Image Sept

Romain Duchez Laurence Heilbronn Claire Doligez Tel.: +33 (0)4 78 87 20 00 Tel.: +33 (0)1 53 70 74 64 Tel.: +33 (0)1 53 70 74 48 media@biomerieux.com lheilbronn@image7.fr cdoligez@image7.fr

APPENDIX 1: QUARTERLY SALES DETAILS

Sales by Application in € millions and % Change in Sales by Application

	First quarter		Second quarter		Third quarter		9 months
	2023	2022	2023	2022	2023	2022	2023	2022
Clinical applications	760.4	703.8	723.6	687.9	760.9	763.0	2,244.8	2,154.7
Molecular biology	352.7	320.1	312.6	303.2	327.9	333.5	993.1	956.8
Microbiology	299.6	269.0	309.6	273.2	321.6	311.8	930.9	853.9
Immunoassays	95.6	104.5	91.6	93.9	94.2	101.4	281.4	299.8
Other lines(1)	12.5	10.2	9.8	17.6	17.1	16.4	39.4	44.2
Industrial Applications(2)	145.4	133.3	140.8	132.9	137.5	139.0	423.7	405.2
TOTAL SALES	905.7	837.1	864.3	820.9	898.4	902.0	2,668.5	2,559.9

(1) Including mainly BioFire Defense and R&D-related revenue arising on clinical applications

(2) Including R&D-related revenue arising on industrial applications.

	First quarter		Second quarter		Third quarter		9 months
	As reported	Like-for like(3)	As reported	Like-for like(3)	As reported	Like-for like(3)	As reported	Like-for like(3)
Clinical applications	+8.0%	+7.2%	+5.2%	+9.1%	-0.3%	+7.2%	+4.2%	+7.9%
Molecular biology	+10.2%	+7.4%	+3.1%	+6.1%	-1.7%	+5.5%	+3.8%	+6.3%
Microbiology	+11.4%	+11.9%	+13.3%	+17.9%	+3.2%	+10.8%	+9.0%	+13.4%
Immunoassays	-8.6%	-6.9%	-2.4%	+2.6%	-7.0%	+0.5%	-6.1%	-1.4%
Other lines(1)	+23.0%	+18.6%	-44.4%	-42.1%	+4.4%	+18.9%	-10.8%	-0.4%
Industrial Applications(2)	+9.0%	+9.0%	+5.9%	+9.6%	-1.0%	+6.3%	+4.6%	+8.3%
TOTAL SALES	+8.2%	+7.5%	+5.3%	+9.2%	-0.4%	+7.1%	+4.2%	+8.0%

(1) Including mainly BioFire Defense and R&D-related revenue arising on clinical applications

(2) Including R&D-related revenue arising on industrial applications.

(3) At constant exchange rates and scope of consolidation.

Sales by Region in € millions and % Change in Sales by Region

	First quarter		Second quarter		Third quarter		9 months
	2023	2022	2023	2022	2023	2022	2023	2022
Americas North America Latin America	455.4 402.7 52.7	413.0 365.3 47.7	428.5 369.2 59.3	418.7 366.4 52.2	439.8 379.6 60.2	454.6 398.4 56.2	1,323.7 1,151.5 172.2	1,287.0 1,130.8 156.2
Europe (1)	287.6	270.0	283.1	267.4	293.1	274.4	863.8	811.0
Asia Pacific	162.7	154.1	152.8	134.8	165.5	173.0	481.0	461.9
TOTAL SALES	905.7	837.1	864.3	820.9	898.4	902.0	2,668.5	2,559.9

(1) Including the Middle East and Africa.

	First quarter		Second quarter		Third quarter		9 months
	As reported	Like-for like(3)	As reported	Like-for like(3)	As reported Like-for	like(3)	As reported Like-for	like(3)
Americas	+10.2%	+6.5%	+2.4%	+5.7%	-3.3%	+5.7%	+2.9%	+6.0%
North America	+10.2%	+5.6%	+0.8%	+3.1%	-4.7%	+2.9%	+1.8%	+3.8%
Latin America	+10.5%	+13.6%	+13.5%	+24.3%	+7.1%	+26.4%	+10.3%	+21.8%
Europe (1)	+6.6%	+8.2%	+5.9%	+8.3%	+6.8%	+9.7%	+6.5%	+9.1%
Asia Pacific	+5.6%	+8.7%	+13.3%	+21.6%	-4.4%	+6.5%	+4.1%	+11.6%
TOTAL SALES	+8.2%	+7.5%	+5.3%	+9.2%	-0.4%	+7.1%	+4.2%	+8.0%

(1) Including the Middle East and Africa. (2) At constant exchange rates and scope of consolidation.